Publications

Bendamustine, lenalidomide, and dexamethasone (BRD) is highly effective with durable responses in relapsed multiple myeloma. American Journal of Hematology. 2015.

Allosteric Communication across STAT3 Domains Associated with STAT3 Function and Disease-Causing Mutation. J Mol Biol. 2016.

Daratumumab montherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomized, phase 2 trial . Lancet. 2016.

Consolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents . Curr Hematol Malig Rep. 2016.

Treatment of Multiple Myeloma: Finding the Right Combination . Oncology (Williston Park). 2016.

Moving Beyond Autologous Transplantation in Multiple Myeloma: Consolidation, Maintenance, Allogeneic Transplant, and Immune Therapy . Am Soc Clin Oncol Educ Book. 2016.

Heavy/light chain ration normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study . Br J Haematol. 2016.

Oncology in primary care. Lippincott Williams & Wilkins 2013. Chapter 70, HIV and other immunosuppression related malignancies. ISBN: 978-1-4511-1149-1.

How to think about risk in myeloma . Clin Lymphoma Myeloma Leuk. 2016.

A Phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in relapsed/refractory multiple myeloma . Cancer. 2016.

POINT: Routine Use of Autologous Stem Cell Transplantation in Multiple Myeloma . Oncology (Williston Park). 2016.

Role of SUMO Activating Enzyme in Cancer Stem Cell Maintenance and Self-renewal . Nat Commun. 2016.